Zydus Lifesciences slipped nearly 3% to Rs 933.40 on BSE after the pharma firm said USFDA had concluded the inspection of its plant with 10 observations.
"We wish to inform that the USFDA conducted an inspection at the injectable manufacturing site situated at Jarod , near Vadodara. The inspection was conducted from April 15 to April 23, 2024. The inspection closed with 10 observations", the company said in an exchange filing.
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner, it added.
"We wish to inform that the USFDA conducted an inspection at the injectable manufacturing site situated at Jarod , near Vadodara. The inspection was conducted from April 15 to April 23, 2024. The inspection closed with 10 observations", the company said in an exchange filing.
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner, it added.
